10 December 2020
New Reporting Channels for Adverse Reaction Reports From Healthcare Professionals
From 1 January 2021 the adverse drug reaction reports (ADR) are to be sent directly to Swissmedic and not to one of the six Regional Pharmacovigilance Centres.
For further information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar